Cerus Corporation (CERS) Earnings Call Transcripts

Cerus Corporation's Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, Cerus Corporation reported product revenue of $53.7 million, reflecting a 24% year-over-year increase, driven by strong performance in both the U.S. platelet franchise and the IFC business. The company raised its full-year product revenue guidance to a range of $227 million to $231 million, indicating a growth of 10% to 12% compared to 2025. Management expressed confidence in the underlying demand for INTERCEPT, highlighting a positive outlook for continued growth and innovation in the coming quarters.

Reported metrics

Guidance from management

Management raised full-year 2026 product revenue guidance to $227 million to $231 million and IFC revenue guidance to $22 million to $24 million, reflecting strong demand and confidence in growth prospects.

What management said

Yes. Thanks, Mark. I think right now, it's probably safe to assume that it will be in the first half 2027 approval time line, just given that we don't know what questions ANSM will ask and the time line for our responding to those questions. I think that's the timing you should be looking at. I mean I think we'll have a lot more clarity through the year-end. I think specifically as we think about our Q3 earnings call...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of the high growth rates, particularly in the IFC business, and the potential impact of ongoing inflationary pressures on gross margins. Additionally, there were questions about the timing of regulatory approvals for new products and their implications for revenue generation.

Main topics on the call

• Revenue Growth Acceleration — Cerus achieved a product revenue of $53.7 million, up 24% year-over-year, driven by strong demand in the platelet franchise and IFC business. Management noted, "Based on our better-than-expected start to the year... we a...
• Guidance Increase — The company raised its full-year revenue guidance for IFC to $22 million to $24 million, reflecting a growth of approximately 30% to 40%. Vivek Jayaraman stated, "We see continued solid platelet growth in both geographie...
• International Market Performance — Cerus reported strong international growth, particularly in EMEA, with revenues growing by 28%. Management highlighted, "France was the first country of scale to fully adopt INTERCEPT... this contract renewal is a strong...
• Gross Margin Challenges — The first quarter gross margin was 52%, down from 58.8% in the prior year, attributed to inflationary pressures and foreign currency impacts. Kevin Green noted, "We expect that to be the case for the remainder of the yea...

Read the full Cerus Corporation transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 34 Cerus Corporation earnings call transcripts on record, spanning February 20, 2020 to July 30, 2026. Based on this history, Cerus Corporation reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CERS

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

34

First call

February 20, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly